Novoprotein Scientific Inc. (SHA:688137)
China · Delayed Price · Currency is CNY 51.62
-2.26 (-4.19%)
At close: May 12, 2026
Novoprotein Scientific Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 150.24 | 146.44 | 127.4 | 153.05 | 264.33 | 341.79 |
Other Revenue | - | - | 0.15 | 0.14 | 0.22 | 0.11 |
| 150.24 | 146.44 | 127.56 | 153.19 | 264.55 | 341.9 | |
Revenue Growth (YoY) | 11.36% | 14.80% | -16.73% | -42.09% | -22.62% | 90.11% |
Cost of Revenue | 46.59 | 48.15 | 73.47 | 70.69 | 54.3 | 54.55 |
Gross Profit | 103.65 | 98.29 | 54.08 | 82.5 | 210.25 | 287.35 |
Selling, General & Admin | 98.64 | 100.05 | 101.09 | 87.84 | 82.94 | 69.29 |
Research & Development | 66.67 | 64.06 | 49.92 | 44.79 | 41.1 | 34.1 |
Other Operating Expenses | 0.99 | 0.86 | 1.29 | 0.67 | 3.01 | 3.9 |
Operating Expenses | 166.3 | 164.98 | 154.39 | 131.72 | 128.27 | 111.17 |
Operating Income | -62.65 | -66.69 | -100.31 | -49.22 | 81.98 | 176.17 |
Interest Expense | - | - | -3.59 | -3.59 | -4.05 | -1.8 |
Interest & Investment Income | - | 0.27 | 41.48 | 49.42 | 9.07 | 2.39 |
Currency Exchange Gain (Loss) | - | - | 0.71 | 0.65 | 2.84 | -0.81 |
Other Non Operating Income (Expenses) | 25.22 | 28.34 | -0.43 | -0.49 | -0.16 | -0.18 |
EBT Excluding Unusual Items | -37.43 | -38.08 | -62.14 | -3.23 | 89.69 | 175.77 |
Gain (Loss) on Sale of Investments | - | - | -1.8 | -1.75 | 3.55 | -0.14 |
Gain (Loss) on Sale of Assets | 0.73 | 0.73 | 0.05 | -0.09 | -0.04 | 0.03 |
Asset Writedown | -29.32 | -33.02 | -6.61 | - | - | -0.15 |
Other Unusual Items | - | - | 16.29 | 11.29 | 12.98 | 0.72 |
Pretax Income | -66.01 | -70.37 | -54.22 | 6.22 | 106.18 | 176.23 |
Income Tax Expense | 10.57 | 7.41 | 0.2 | -6.62 | 15.46 | 27.22 |
Net Income | -76.58 | -77.78 | -54.42 | 12.84 | 90.72 | 149.01 |
Net Income to Common | -76.58 | -77.78 | -54.42 | 12.84 | 90.72 | 149.01 |
Net Income Growth | - | - | - | -85.84% | -39.12% | 79.42% |
Shares Outstanding (Basic) | 70 | 70 | 70 | 71 | 57 | 40 |
Shares Outstanding (Diluted) | 70 | 70 | 70 | 71 | 57 | 40 |
Shares Change (YoY) | -0.43% | 0.45% | -2.23% | 25.05% | 42.83% | 151.52% |
EPS (Basic) | -1.09 | -1.11 | -0.78 | 0.18 | 1.59 | 3.73 |
EPS (Diluted) | -1.09 | -1.11 | -0.78 | 0.18 | 1.59 | 3.73 |
EPS Growth | - | - | - | -88.68% | -57.37% | -28.67% |
Free Cash Flow | -92.34 | -92.25 | -31.57 | 24.22 | -33.39 | 1.02 |
Free Cash Flow Per Share | -1.31 | -1.32 | -0.45 | 0.34 | -0.58 | 0.03 |
Dividend Per Share | - | - | - | 0.500 | 0.500 | - |
Gross Margin | 68.99% | 67.12% | 42.40% | 53.85% | 79.47% | 84.05% |
Operating Margin | -41.70% | -45.54% | -78.64% | -32.13% | 30.99% | 51.53% |
Profit Margin | -50.97% | -53.12% | -42.66% | 8.38% | 34.29% | 43.58% |
Free Cash Flow Margin | -61.46% | -62.99% | -24.75% | 15.81% | -12.62% | 0.30% |
EBITDA | -49.28 | -53.63 | -88.48 | -39.11 | 90.5 | 180.01 |
EBITDA Margin | -32.80% | -36.62% | -69.37% | -25.53% | 34.21% | 52.65% |
D&A For EBITDA | 13.36 | 13.06 | 11.83 | 10.11 | 8.52 | 3.83 |
EBIT | -62.65 | -66.69 | -100.31 | -49.22 | 81.98 | 176.17 |
EBIT Margin | -41.70% | -45.54% | -78.64% | -32.13% | 30.99% | 51.53% |
Effective Tax Rate | - | - | - | - | 14.56% | 15.45% |
Revenue as Reported | - | - | 127.56 | 153.19 | 264.55 | 341.9 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.